Faced with fresh concerns about Hemlibra’s safety, Roche spells out what it knows about 5 deaths
Roche is offering some additional details on the 5 deaths they’ve recorded among hemophilia patients taking Hemlibra, repeating their assertion that the risk/benefit profile of the would-be blockbuster remains unchanged as they conduct an “ongoing” investigation of two recent cases.
According to a spokesperson, 2 new deaths were recorded recently which physicians linked to a pre-existing condition in one case and major vascular surgery in another. Those cases followed deaths associated with a rectal hemorrhage and two intracranial hemorrhages.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.